<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293356</url>
  </required_header>
  <id_info>
    <org_study_id>BPL-Nim-NPC-2</org_study_id>
    <nct_id>NCT02293356</nct_id>
  </id_info>
  <brief_title>Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma</brief_title>
  <official_title>Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotech Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotech Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed as an open, single group, multi-center, phase 4 clinical
      study to assess the safety of Nimotuzumab in the treatment of nasopharyngeal carcinoma and to
      provide a more reasonable basis for clinical drug programs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study is designed as an open, single group, multi-center, phase 4 clinical
      study to assess the safety of Nimotuzumab in the treatment of nasopharyngeal carcinoma and to
      provide a more reasonable basis for clinical drug programs.

      Subjects who meet the inclusion/exclusion criteria are administered of Nimotuzumab based on
      medication instructions or adjusted by clinicians according to the treatment. In case of the
      progression of disease, unacceptable toxicity, withdrawal of the consent, or judgment by
      investigator that the treatment needs to be stopped, the treatment of Nimotuzumab is stopped.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of the treatment with Nimotuzumab(NCI Common Terminology Criteria for Adverse Events v4.03)</measure>
    <time_frame>up to 30 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg,Once a weekï¼ŒIntravenous infusion over 60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab Injection</intervention_name>
    <description>patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.</description>
    <arm_group_label>Nimotuzumab Injection</arm_group_label>
    <other_name>Taixinsheng</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically or cytologically confirmed nasopharyngeal carcinoma

          2. Sex and age without limiting

          3. Treatment without limiting

          4. Subjects with reproductive potential (males and females) willing to use reliable means
             of contraception

          5. Able and willing to give written informed consent and comply with the requirements of
             the study protocol

        Exclusion Criteria:

          1. Patients with severe allergies or idiosyncratic constitution

          2. Women who are pregnant (determined by urine pregnancy test)or breast feeding

          3. Any other severe complications or functional disorder of organ systems, which will
             affect the evaluation of safety of patients or will interfere with the test drug
             according to the researcher's point of view
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>li gao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li gao, PhD</last_name>
    <phone>13801371743</phone>
    <email>li_gao2008@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute &amp; Hospital.Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>li gao, PhD</last_name>
      <phone>13801371743</phone>
      <email>li_gao2008@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

